Search Results: Living with SMA issues
Cure SMA Announces Expanded Phase 3 of Real World Evidence Collaboration
Cure SMA is pleased to announce the launch of an expanded Phase 3 of the Real World Evidence Collaboration. The collaboration was established to leverage […]
Read More ›International SMA Meeting
International SMA Patient Advocacy Group Meeting 2025 International SMA Patient Advocacy Group Meeting Cure SMA’s second International SMA Patient Advocacy Group Meeting was held on […]
Read More ›Thank You for an Amazing 2023 Annual SMA Conference!
Thank you to everyone who attended the 2023 Annual SMA Conference at Disney’s Yacht & Beach Club in Orlando, Florida! It was an impactful weekend […]
Read More ›Cure SMA Applauds Federal Agency Decision that Should Lead to Better Insurance Coverage for Seat Elevation Systems in Power Wheelchairs
Thanks to the advocacy of individuals with spinal muscular atrophy (SMA) and others, the Centers for Medicare and Medicaid Services (CMS) now considers seat elevation […]
Read More ›SMA Awareness Month
SMA Awareness Month 2025 Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease that affects the motor nerve cells in the spinal cord and impacts […]
Read More ›Participate in Annual Cure SMA Community Update Survey – Open Now!
Last year presented the us with unique challenges, some we are still managing today. However, it has also reinforced the importance of understanding what the […]
Read More ›Cure SMA Funds Over $9 Million in New and Ongoing Research in FY20
During our past fiscal year—from July 1, 2019 to June 30, 2020—Cure SMA funded more than $9 million in new and ongoing research and care […]
Read More ›Cure SMA to Meet with FDA for Critical Path Innovation Meeting
We are excited to share with the SMA community that the U.S. Food and Drug Administration (FDA) has granted Cure SMA a Critical Path Innovation […]
Read More ›Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults with SMA
Genentech, a member of the Roche Group, shared two-year data from Part 1 of its pivotal SUNFISH trial in people aged 2-25 […]
Read More ›Genentech’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 SMA
Genentech, a member of the Roche Group, today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged […]
Read More ›